GlassScriptPhysician profile
James Hutcheson
NPI 1679577233
$838.29
in general payments reported to CMS, 2019-2025
12 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $39.60 · 2021: $103 · 2022: $65.62 · 2023: $203 · 2024: $136 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451 · Consulting Fee: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.19 |
| Consulting Fee | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $222.98 | 2019-2025 | Dupixent |
| Alk-Abello, INC | $130.98 | 2020-2023 | Timothy, Standardized, Standardized Mite D. Farinae, Alternaria Tenuis |
| Glaxosmithkline, LLC. | $117.61 | 2023-2025 | Nucala |
| Medtronic, INC. | $113.43 | 2023 | Propel, Merocel |
| Acclarent, INC | $94.15 | 2019 | |
| Merck Sharp & Dohme LLC | $40.62 | 2021-2023 | |
| Amgen INC. | $23.94 | 2025 | Tezspire |
| Aerin Medical INC. | $23.37 | 2024 | |
| Genentech USA, INC. | $20.73 | 2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $20.13 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $19.09 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hutcheson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.